Real-world use of intravenous ferric derisomaltose in Brazilian patients with iron deficiency anemia.
Source: PubMed, NCBI / U.S. National Library of Medicine
Iron deficiency anemia remains a major global health concern, especially among women, children, and people with chronic illnesses. Oral iron therapy is the standard treatment, but it is often limited by gastrointestinal side effects or poor absorption. Intravenous ferric derisomaltose is a newer formulation that allows high-dose, rapid iron replenishment with a favorable safety profile. This study aimed to assess the effectiveness and safety of intravenous ferric derisomaltose in patients with iron deficiency anemia who could not tolerate or did not respond to oral iron. This was a prospective, open-label, single-center trial conducted in São Paulo, Brazil. Adult patients (≥18 years) with iron deficiency anemia received 1 or 2 infusions of intravenous ferric derisomaltose (up to 1000 mg per infusion). Hematologic and iron parameters were measured at baseline, Week 4, and Week 8. Safety outcomes included adverse events and serum phosphate levels. Thirty patients were treated with 25 requiring a second infusion. Significant increases in hemoglobin, serum ferritin, transferrin saturation, and reticulocyte hemoglobin content were seen at both time points. By Week 8, 81% achieved a hemoglobin increase ≥2 g/dL, and 54% achieved an increase of ≥3 g/dL. Four (8%) mild adverse events occurred and three patients (10%) experienced transient, asymptomatic hypophosphatemia, which resolved without intervention. This study contributes to the growing evidence suppor
Abstract
Iron deficiency anemia remains a major global health concern, especially among women, children, and people with chronic illnesses. Oral iron therapy is the standard treatment, but it is often limited by gastrointestinal side effects or poor absorption. Intravenous ferric derisomaltose is a newer formulation that allows high-dose, rapid iron replenishment with a favorable safety profile. This study aimed to assess the effectiveness and safety of intravenous ferric derisomaltose in patients with iron deficiency anemia who could not tolerate or did not respond to oral iron. This was a prospective, open-label, single-center trial conducted in São Paulo, Brazil. Adult patients (≥18 years) with iron deficiency anemia received 1 or 2 infusions of intravenous ferric derisomaltose (up to 1000 mg per infusion). Hematologic and iron parameters were measured at baseline, Week 4, and Week 8. Safety outcomes included adverse events and serum phosphate levels. Thirty patients were treated with 25 requiring a second infusion. Significant increases in hemoglobin, serum ferritin, transferrin saturation, and reticulocyte hemoglobin content were seen at both time points. By Week 8, 81% achieved a hemoglobin increase ≥2 g/dL, and 54% achieved an increase of ≥3 g/dL. Four (8%) mild adverse events occurred and three patients (10%) experienced transient, asymptomatic hypophosphatemia, which resolved without intervention. This study contributes to the growing evidence supporting the use of intravenous ferric derisomaltose as a safe and effective alternative for distinct populations with iron deficiency anemia. In this real-world clinical setting, the treatment is effective for treating patients with iron deficiency, providing rapid hematologic recovery with a favorable safety profile.